THE RELATIONSHIP BETWEEN PD-1 EXPRESSION AND METABOLIC PET/CT PARAMETERS OF PRIMARY TUMOR IN NSCLC
MEANDROS MEDICAL AND DENTAL JOURNAL, cilt.27, sa.2, ss.219-225, 2026 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 2
- Basım Tarihi: 2026
- Doi Numarası: 10.69601/meandrosmdj.1827430
- Dergi Adı: MEANDROS MEDICAL AND DENTAL JOURNAL
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.219-225
- Recep Tayyip Erdoğan Üniversitesi Adresli: Evet
Özet
Objective: Our study was to investigate the correlation between metabolic tumor parameters of the primary tumor and programmed cell death protein-1 (PD-1) expression of the tumor cell and the value of fluorine18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging in predicting the PD-1 expression in non-small cell lung cancer (NSCLC). Materials and Methods: A total of 79 patients diagnosed with NSCLC were included in this retrospective study. PD-1 expression of tumors was determined by immunohistochemistry staining. All patients had PET/CT scans available at initial staging. The correlation between PD-1 expression of tumor cells and metabolic PET/CT parameters of the primary tumor was evaluated by Spearman correlation analysis. Whether metabolic PET/CT parameters predicted PD-1 expression was evaluated by Receiver operating characteristic (ROC) Curve analysis. Results: No statistically significant relationship has been detected between the metabolic tumor parameters of the primary tumor and other clinicopathological data, or with PD-1 expression in tumor cells. Conclusion: 18F-FDG uptake rate in tumor cells is a non-invasive method that indicates biomarker status in cancer patients. Clinicians use biomarkers such as PD-1 to help them decide whether to start immunotherapy in their patients. In this study, no relationship was found between the metabolic PET/CT parameters and PD-1 expression. Keywords: Immunotherapy, metabolic tumor volume, non-small cell lung cancer, PD-1 expression, positron emission tomography/computed tomography, total lezyon glikolisiz.